The Lefoulon Delalande Foundation honors the lymphatic vascular system
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
The Lefoulon Delalande Foundation awarded its 2023 Scientific Grand Prize to Kari Alitalo from the University of Helsinki and the Wihuri Research Institute in Finland, and to Susan Quaggin from the Feinberg School of Medicine at NorthWestern University in Chicago, USA. The 600,000-euro prize is awarded annually for researchers who significantly contributed to cardiovascular physiology, biology or medicine, and the 2023 edition was equally shared between the two laureates....
Donnan MD, Kenig-Kozlovsky Y, Quaggin SE. The lymphatics in kidney health and disease. Nat Rev Nephrol 2021;17:655-75. DOI: https://doi.org/10.1038/s41581-021-00438-y
Brakenhielm E, Alitalo K. Cardiac lymphatics in health and disease. Nat Rev Cardiol 2019;16:56-68. DOI: https://doi.org/10.1038/s41569-018-0087-8
Oliver G, Kipnis J, Randolph GJ, Harvey NL. The lymphatic vasculature in the 21st Century: novel functional roles in homeostasis and disease. Cell 2020;182:270-96. DOI: https://doi.org/10.1016/j.cell.2020.06.039
Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995;92:3566-70. DOI: https://doi.org/10.1073/pnas.92.8.3566
Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-8. Erratum in: EMBO J 1996;15:1751. DOI: https://doi.org/10.1002/j.1460-2075.1996.tb00359.x
Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004;5:74-80. DOI: https://doi.org/10.1038/ni1013
Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000;25:153-9. DOI: https://doi.org/10.1038/75997
Leppäpuska IM, Hartiala P, Suominen S, et al. Phase 1 Lymfactin® study: 24-month efficacy and safety results of combined adenoviral VEGF-C and lymph node transfer treatment for upper extremity lymphedema. J Plast Reconstr Aesthet Surg 2022;75:3938-45. DOI: https://doi.org/10.1016/j.bjps.2022.08.011
Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454:656-60. DOI: https://doi.org/10.1038/nature07083
Thomson BR, Heinen S, Jeansson M, et al. A lymphatic defect causes ocular hypertension and glaucoma in mice. J Clin Invest 2014;124:4320-4. DOI: https://doi.org/10.1172/JCI77162
Souma T, Tompson SW, Thomson Bret al. Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity. J Clin Invest 2016;126:2575-87. DOI: https://doi.org/10.1172/JCI85830
Thomson BR, Souma T, Tompson SW, et al. Angiopoietin-1 is required for Schlemm's canal development in mice and humans. J Clin Invest 2017;127:4421-36. DOI: https://doi.org/10.1172/JCI95545
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.